Dr. Charles Brenner
City of Hope National Medical Center
Biography & Research Background
Charles Brenner, PhD, holds the Alfred E. Mann Family Foundation Chair in Diabetes and Cancer Metabolism at City of Hope National Medical Center and serves as Chief Scientific Advisor at Niagen Bioscience. In 2004, Dr. Brenner discovered the nicotinamide riboside kinase (NRK) pathway, establishing NR as a vitamin precursor to NAD+. He led the first clinical trial establishing NR safety and oral bioavailability in humans (2016, Nature Communications). His foundational work includes 'Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes' (2004) and 'Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition' (2008). Charles Brenner is being referenced as one of the leading scientists involved in NAD+ research. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
External Profiles
Authored Research Profiles (1)
Dr. Charles Brenner is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
Dr. Charles Brenner is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.